Two Dividend Kings share an equal-length streak of 55 years of consecutive dividend raises, but they present contrasting profiles for investors. Johnson & Johnson (JNJ) has delivered remarkable price performance over the past year while continuing to expand revenue. Becton Dickinson (BDX) stands out for the pace of its top-line growth and a substantial fair value gap that may indicate relative undervaluation.
Snapshot of key metrics
| Metric | Johnson & Johnson (JNJ) | Becton Dickinson (BDX) |
|---|---|---|
| Price | $257.60 | $170.66 |
| Dividend Streak | 55 years | 55 years |
| Dividend Yield | 2.1% | 2.5% |
| 1Y Return | +53.0% | +25.4% |
| 6M Return | +12.3% | +5.8% |
| YTD Return | +24.6% | +13.0% |
| Revenue Growth | +8.1% | +15.5% |
| P/E (LTM) | 29.5x | 28.5x |
| RSI (14d) | 53.7 | 70.3 |
| Fair Value Upside | +2.1% | +25.6% |
| Market Cap | $621.75B | $46.92B |
Johnson & Johnson - steady strength with recent acceleration
Johnson & Johnson is traditionally viewed as a blue-chip income name, but recent performance resembles that of a growth-oriented stock. The one-year return of +53.0% is notable for a Dividend King. Revenue has progressed in a steady three-year series from $85.16B to $88.82B to $94.19B, reflecting consistent expansion at the top line.
- Return on equity is reported at 25.7%, indicating high capital efficiency for a large healthcare company.
- Net income margin stands at 21.5%, meaning roughly one in five dollars of revenue reached the bottom line.
- RSI at 53.7 signals healthy momentum without an overbought technical reading.
- A cautionary note: the fair value upside is only +2.1%, implying much of the company's prospects may already be reflected in the current share price.
Becton Dickinson - faster top-line gains and a valuation gap
Becton Dickinson occupies a different role within the Dividend Kings cohort. It delivered revenue growth from $19.37B to $21.84B, a +15.5% increase that leads the screen. At a share price of $170.66 and a fair value near $214.42, BDX combines dividend longevity with what appears to be a material valuation discount.
- The calculated fair value upside is +25.6%, suggesting the market may be underpricing the company relative to the valuation estimate.
- RSI at 70.3 shows technical strength and elevated momentum - a level that may presage near-term consolidation.
- The dividend yield of 2.5% slightly exceeds JNJ's yield, offering modestly higher income for yield-focused portfolios.
- On the margin side, the company reports an ROE of 6.7% and a net income margin of 5.1%, which are relatively low and reflect a business that is volume- and device-driven rather than margin-heavy.
Portfolio implications - complementary roles
Viewed together, the two names form a barbell of characteristics. Johnson & Johnson functions as a defensive anchor with strong profitability metrics and recent outsized price appreciation, but limited remaining fair value upside at current levels. Becton Dickinson offers stronger revenue momentum and a sizable fair value cushion, while carrying thinner margins and a higher RSI reading that investors may monitor for short-term pullbacks.
Both companies remain members of the elite club of firms that have raised dividends for 55 consecutive years, and neither appears to be relying solely on legacy cash flow. Instead, each displays active growth or valuation traits that distinguish its investment case.
Summary
Johnson & Johnson combines elite margins, a substantial one-year return of +53.0%, and limited fair value upside of +2.1%. Becton Dickinson shows the fastest revenue growth in the screen at +15.5% and a 25.6% fair value upside, but reports lower profitability metrics. Together they provide contrasting exposures inside the longest-running dividend raisers.